Browsing by Author "Bhupendra Sahu"

Now showing 1 - 2 of 2

Intranasal micellar curcumin for the treatment of chronic asthma
(Editions de Sante, 2022) Ruchi Chawla; Bhupendra Sahu; Mohini Mishra; Varsha Rani; Rashmi Singh
Curcumin is a natural phytoconstituent obtained from the rhizomes of Curcuma longa (turmeric) and is known for its diverse anti-oxidant and anti-inflammatory benefits, but its clinical utility is limited by its poor aqueous solubility and rapid metabolism, which ultimately affects its bioavailability. The present study is focused on the formulation of curcumin loaded micellar dispersion for intranasal delivery for the treatment of chronic asthma. Micellar dispersion was prepared by film formation method using poly-(ethylene oxide)-block-distearoyl phosphatidyl-ethanolamine (mPEG5000-DSPE) as lipid surfactant and characterized for its physic-chemical properties. The curcumin micelles were evaluated for their anti-asthmatic action in ovalbumin (OVA)-induced allergic asthma model in male wistar rats against standard drug dexamethasone. The micelles showed mean particle size in the range of 20.03 nm–26.48 nm. The micellar dispersion exhibited negative zeta potential in the range of −26.22 to −25.52 mV. Incorporation of curcumin into micelles helped in enhancing the solubility of curcumin besides providing it protection against degradation. In vitro studies showed sustained relase of curcumin up to 36 h. A 14- fold increase in the bioaviability of the curcumin was measured when administered as micelles. In addition, 4.4- fold higher concentration of drug was measured in the lungs for micellar curcumin. Comparable reduction in the levels of intracellular ROS was observed for i.n. curcumin-micelles (approx.57.6%) and dexamethasone (59.3%). Also, micellar curcumin produced significant supression (p < 0.05) in the release of nitric oxide. Through the present study, we can suggest the potential application of curcumin micelles in the treatment of asthma. © 2021 Elsevier B.V.
Negatively charged liposomes of sertraline hydrochloride: Formulation, characterization and pharmacokinetic studies
(Editions de Sante, 2020) Tejpratap Chauhan; Varsha Rani; Bhupendra Sahu; Adity Sharma; Subhash Chand Kheruka; Sanjay Gambhir; Veeresh Dube; Lalit M. Aggarwal; Ruchi Chawla
The present study was carried out with an objective to study the extent of delivery of negatively charged liposomes of sertraline hydrochloride to brain via intravenous route for treatment of depressive –like symptoms. Liposomes of sertraline hydrochloride were formulated by film hydration technique using cholesterol, hydrogenated soya phosphatidylcholine-L-α-phosphatidylcholine, and distearoyl phosphatidyl glycerol sodium. Uniform sized vesicles with porous surface morphology with vesicle size of 151.59 nm were prepared. Radioactive imaging performed using 99mTcO4 showed ~5% of uptake of labelled liposomes in brain within 2 h of administration. On administration of liposomes and free drug suspension, approximately, 205.06 ng/ml and 87.18 ng/ml of sertraline were estimated in brain at 36 h. The liposomes can be transported by transcelluar transport which includes phagocytosis and the use of phosphatidylcholine enhances macrophage internalization and delivery to brain. The study indicated significantly higher concentration of sertraline in brain after 36 h, on administration of liposomes as compared to free sertraline suspension. © 2020 Elsevier B.V.